DWA
TNYA icon

Dorsey Wright & Associates’s Tenaya Therapeutics TNYA Stock Holding History

Dorsey Wright & Associates’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,577
Closed -$21K – 328
2023
Q2 		$21K Buy
+3,577
New +$20.8K 0.01% 251

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Dorsey Wright & Associates's TNYA Position: Q3 2023 in Review

Dorsey Wright & Associates sold out of Tenaya Therapeutics (TNYA) in Q3 2023, closing a stake of 3,577 shares — an estimated $21K sold.

Dorsey Wright & Associates first reported a position in TNYA in Q2 2023 and held it in 1 quarter. The position peaked at $21K in Q2 2023. 76 funds tracked by Wall St. Rank hold TNYA as of Q3 2023.

  • Dorsey Wright & Associates reported no remaining Tenaya Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 3,577 Tenaya Therapeutics shares in Q3 2023, an estimated $21K.
  • Dorsey Wright & Associates first reported a position in Tenaya Therapeutics in Q2 2023 and held it in 1 quarter.
  • Dorsey Wright & Associates's Tenaya Therapeutics position peaked at $21K in Q2 2023.
  • 76 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q3 2023.

Based on Dorsey Wright & Associates's 13F filing for Q3 2023, filed 7 Nov 2023.